Intrinsic value of Natus Medical - BABY

Previous Close

$32.15

  Intrinsic Value

$23.92

stock screener

  Rating & Target

sell

-26%

Previous close

$32.15

 
Intrinsic value

$23.92

 
Up/down potential

-26%

 
Rating

sell

We calculate the intrinsic value of BABY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  31.20
  28.58
  26.22
  24.10
  22.19
  20.47
  18.92
  17.53
  16.28
  15.15
  14.14
  13.22
  12.40
  11.66
  10.99
  10.39
  9.85
  9.37
  8.93
  8.54
  8.19
  7.87
  7.58
  7.32
  7.09
  6.88
  6.69
  6.52
  6.37
  6.23
Revenue, $m
  657
  845
  1,067
  1,324
  1,618
  1,949
  2,318
  2,724
  3,167
  3,647
  4,163
  4,713
  5,297
  5,915
  6,565
  7,248
  7,962
  8,708
  9,486
  10,296
  11,139
  12,015
  12,926
  13,872
  14,856
  15,878
  16,941
  18,046
  19,196
  20,392
Variable operating expenses, $m
  551
  698
  872
  1,074
  1,304
  1,564
  1,854
  2,173
  2,521
  2,897
  3,267
  3,699
  4,158
  4,643
  5,153
  5,689
  6,250
  6,835
  7,446
  8,082
  8,743
  9,431
  10,146
  10,889
  11,661
  12,463
  13,297
  14,165
  15,067
  16,007
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  551
  698
  872
  1,074
  1,304
  1,564
  1,854
  2,173
  2,521
  2,897
  3,267
  3,699
  4,158
  4,643
  5,153
  5,689
  6,250
  6,835
  7,446
  8,082
  8,743
  9,431
  10,146
  10,889
  11,661
  12,463
  13,297
  14,165
  15,067
  16,007
Operating income, $m
  107
  147
  195
  250
  313
  385
  464
  551
  647
  750
  895
  1,014
  1,139
  1,272
  1,412
  1,559
  1,712
  1,873
  2,040
  2,214
  2,396
  2,584
  2,780
  2,983
  3,195
  3,415
  3,643
  3,881
  4,128
  4,386
EBITDA, $m
  179
  230
  291
  361
  441
  531
  631
  742
  863
  994
  1,134
  1,284
  1,443
  1,612
  1,789
  1,975
  2,169
  2,373
  2,585
  2,805
  3,035
  3,274
  3,522
  3,780
  4,048
  4,326
  4,616
  4,917
  5,230
  5,556
Interest expense (income), $m
  0
  8
  13
  19
  26
  34
  43
  53
  65
  77
  91
  106
  122
  139
  157
  176
  196
  217
  239
  263
  287
  312
  338
  365
  393
  423
  453
  485
  518
  552
  587
Earnings before tax, $m
  98
  134
  176
  224
  280
  342
  411
  487
  569
  659
  789
  892
  1,001
  1,115
  1,236
  1,363
  1,495
  1,633
  1,778
  1,928
  2,084
  2,246
  2,415
  2,590
  2,772
  2,962
  3,159
  3,363
  3,576
  3,798
Tax expense, $m
  27
  36
  47
  61
  75
  92
  111
  131
  154
  178
  213
  241
  270
  301
  334
  368
  404
  441
  480
  520
  563
  606
  652
  699
  749
  800
  853
  908
  966
  1,026
Net income, $m
  72
  98
  128
  164
  204
  249
  300
  355
  416
  481
  576
  651
  730
  814
  902
  995
  1,091
  1,192
  1,298
  1,407
  1,521
  1,640
  1,763
  1,891
  2,024
  2,162
  2,306
  2,455
  2,611
  2,773

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  931
  1,197
  1,511
  1,875
  2,291
  2,760
  3,283
  3,858
  4,486
  5,166
  5,896
  6,676
  7,504
  8,378
  9,300
  10,266
  11,278
  12,335
  13,436
  14,584
  15,777
  17,019
  18,309
  19,649
  21,042
  22,490
  23,995
  25,561
  27,189
  28,884
Adjusted assets (=assets-cash), $m
  931
  1,197
  1,511
  1,875
  2,291
  2,760
  3,283
  3,858
  4,486
  5,166
  5,896
  6,676
  7,504
  8,378
  9,300
  10,266
  11,278
  12,335
  13,436
  14,584
  15,777
  17,019
  18,309
  19,649
  21,042
  22,490
  23,995
  25,561
  27,189
  28,884
Revenue / Adjusted assets
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
Average production assets, $m
  377
  485
  612
  760
  929
  1,119
  1,330
  1,564
  1,818
  2,093
  2,389
  2,705
  3,041
  3,395
  3,769
  4,160
  4,570
  4,998
  5,445
  5,910
  6,394
  6,897
  7,419
  7,963
  8,527
  9,114
  9,724
  10,358
  11,018
  11,705
Working capital, $m
  60
  78
  98
  122
  149
  179
  213
  251
  291
  336
  383
  434
  487
  544
  604
  667
  733
  801
  873
  947
  1,025
  1,105
  1,189
  1,276
  1,367
  1,461
  1,559
  1,660
  1,766
  1,876
Total debt, $m
  243
  351
  478
  626
  794
  984
  1,196
  1,429
  1,683
  1,959
  2,254
  2,570
  2,905
  3,260
  3,633
  4,024
  4,434
  4,862
  5,308
  5,773
  6,256
  6,759
  7,281
  7,824
  8,388
  8,975
  9,584
  10,218
  10,878
  11,564
Total liabilities, $m
  377
  485
  612
  759
  928
  1,118
  1,329
  1,563
  1,817
  2,092
  2,388
  2,704
  3,039
  3,393
  3,766
  4,158
  4,568
  4,995
  5,442
  5,906
  6,390
  6,893
  7,415
  7,958
  8,522
  9,109
  9,718
  10,352
  11,012
  11,698
Total equity, $m
  554
  712
  899
  1,116
  1,363
  1,642
  1,953
  2,296
  2,669
  3,074
  3,508
  3,972
  4,465
  4,985
  5,533
  6,108
  6,710
  7,339
  7,995
  8,677
  9,388
  10,126
  10,894
  11,691
  12,520
  13,382
  14,277
  15,209
  16,178
  17,186
Total liabilities and equity, $m
  931
  1,197
  1,511
  1,875
  2,291
  2,760
  3,282
  3,859
  4,486
  5,166
  5,896
  6,676
  7,504
  8,378
  9,299
  10,266
  11,278
  12,334
  13,437
  14,583
  15,778
  17,019
  18,309
  19,649
  21,042
  22,491
  23,995
  25,561
  27,190
  28,884
Debt-to-equity ratio
  0.440
  0.490
  0.530
  0.560
  0.580
  0.600
  0.610
  0.620
  0.630
  0.640
  0.640
  0.650
  0.650
  0.650
  0.660
  0.660
  0.660
  0.660
  0.660
  0.670
  0.670
  0.670
  0.670
  0.670
  0.670
  0.670
  0.670
  0.670
  0.670
  0.670
Adjusted equity ratio
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595
  0.595

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  72
  98
  128
  164
  204
  249
  300
  355
  416
  481
  576
  651
  730
  814
  902
  995
  1,091
  1,192
  1,298
  1,407
  1,521
  1,640
  1,763
  1,891
  2,024
  2,162
  2,306
  2,455
  2,611
  2,773
Depreciation, amort., depletion, $m
  72
  83
  96
  111
  127
  146
  168
  191
  216
  244
  239
  271
  304
  340
  377
  416
  457
  500
  544
  591
  639
  690
  742
  796
  853
  911
  972
  1,036
  1,102
  1,171
Funds from operations, $m
  144
  181
  224
  274
  331
  396
  467
  546
  632
  725
  815
  922
  1,034
  1,154
  1,279
  1,411
  1,548
  1,692
  1,842
  1,998
  2,161
  2,329
  2,505
  2,687
  2,877
  3,073
  3,278
  3,491
  3,713
  3,943
Change in working capital, $m
  14
  17
  20
  24
  27
  30
  34
  37
  41
  44
  47
  51
  54
  57
  60
  63
  66
  69
  72
  75
  78
  81
  84
  87
  90
  94
  98
  102
  106
  110
Cash from operations, $m
  130
  164
  204
  251
  304
  365
  433
  509
  591
  681
  768
  871
  981
  1,097
  1,219
  1,348
  1,483
  1,624
  1,771
  1,924
  2,083
  2,249
  2,421
  2,600
  2,786
  2,979
  3,180
  3,389
  3,607
  3,833
Maintenance CAPEX, $m
  -29
  -38
  -49
  -61
  -76
  -93
  -112
  -133
  -156
  -182
  -209
  -239
  -271
  -304
  -340
  -377
  -416
  -457
  -500
  -544
  -591
  -639
  -690
  -742
  -796
  -853
  -911
  -972
  -1,036
  -1,102
New CAPEX, $m
  -90
  -108
  -127
  -148
  -169
  -190
  -212
  -233
  -255
  -275
  -296
  -316
  -335
  -355
  -373
  -392
  -410
  -428
  -446
  -465
  -484
  -503
  -523
  -543
  -565
  -587
  -610
  -634
  -660
  -687
Cash from investing activities, $m
  -119
  -146
  -176
  -209
  -245
  -283
  -324
  -366
  -411
  -457
  -505
  -555
  -606
  -659
  -713
  -769
  -826
  -885
  -946
  -1,009
  -1,075
  -1,142
  -1,213
  -1,285
  -1,361
  -1,440
  -1,521
  -1,606
  -1,696
  -1,789
Free cash flow, $m
  11
  18
  28
  42
  60
  82
  110
  143
  180
  224
  263
  316
  375
  438
  506
  579
  657
  738
  824
  914
  1,008
  1,106
  1,209
  1,315
  1,425
  1,540
  1,659
  1,783
  1,911
  2,044
Issuance/(repayment) of debt, $m
  89
  108
  127
  147
  169
  190
  212
  233
  254
  275
  296
  316
  335
  354
  373
  391
  410
  428
  446
  465
  483
  503
  522
  543
  564
  586
  610
  634
  660
  686
Issuance/(repurchase) of shares, $m
  60
  60
  58
  53
  44
  30
  11
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  149
  168
  185
  200
  213
  220
  223
  233
  254
  275
  296
  316
  335
  354
  373
  391
  410
  428
  446
  465
  483
  503
  522
  543
  564
  586
  610
  634
  660
  686
Total cash flow (excl. dividends), $m
  161
  186
  214
  242
  272
  302
  333
  376
  435
  499
  558
  632
  710
  793
  880
  971
  1,066
  1,166
  1,270
  1,379
  1,492
  1,609
  1,731
  1,858
  1,989
  2,126
  2,269
  2,417
  2,571
  2,731
Retained Cash Flow (-), $m
  -132
  -158
  -187
  -217
  -248
  -279
  -311
  -342
  -374
  -404
  -434
  -464
  -493
  -521
  -548
  -575
  -602
  -629
  -656
  -683
  -710
  -738
  -768
  -798
  -829
  -861
  -896
  -931
  -969
  -1,009
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  10
  12
  16
  20
  25
  31
  37
  44
  52
  60
  69
  79
  90
  101
  112
  125
  138
  151
  165
  180
  196
  212
  228
  246
  264
  282
  302
  322
  343
  365
Cash available for distribution, $m
  29
  28
  27
  26
  24
  23
  22
  33
  61
  94
  124
  168
  217
  272
  331
  396
  464
  538
  615
  696
  781
  871
  963
  1,060
  1,161
  1,265
  1,373
  1,485
  1,602
  1,722
Discount rate, %
  5.90
  6.20
  6.50
  6.83
  7.17
  7.53
  7.91
  8.30
  8.72
  9.15
  9.61
  10.09
  10.60
  11.13
  11.68
  12.27
  12.88
  13.52
  14.20
  14.91
  15.65
  16.44
  17.26
  18.12
  19.03
  19.98
  20.98
  22.03
  23.13
  24.29
PV of cash for distribution, $m
  27
  25
  22
  20
  17
  15
  13
  18
  29
  39
  45
  53
  59
  62
  63
  62
  59
  55
  49
  43
  37
  31
  25
  19
  15
  11
  8
  6
  4
  3
Current shareholders' claim on cash, %
  94.6
  90.7
  87.8
  85.8
  84.5
  83.8
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6
  83.6

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company's product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.

FINANCIAL RATIOS  of  Natus Medical (BABY)

Valuation Ratios
P/E Ratio 24.6
Price to Sales 2.8
Price to Book 2.5
Price to Tangible Book
Price to Cash Flow 14.5
Price to Free Cash Flow 15.1
Growth Rates
Sales Growth Rate 1.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -40%
Cap. Spend. - 3 Yr. Gr. Rate -5.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 33.6%
Total Debt to Equity 33.6%
Interest Coverage 0
Management Effectiveness
Return On Assets 7.6%
Ret/ On Assets - 3 Yr. Avg. 7.8%
Return On Total Capital 9.1%
Ret/ On T. Cap. - 3 Yr. Avg. 9.5%
Return On Equity 10.6%
Return On Equity - 3 Yr. Avg. 10.2%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 61.5%
Gross Margin - 3 Yr. Avg. 60.8%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 17.7%
Operating Margin 14.4%
Oper. Margin - 3 Yr. Avg. 13.9%
Pre-Tax Margin 14.4%
Pre-Tax Margin - 3 Yr. Avg. 13.7%
Net Profit Margin 11.3%
Net Profit Margin - 3 Yr. Avg. 10.1%
Effective Tax Rate 21.8%
Eff/ Tax Rate - 3 Yr. Avg. 26.4%
Payout Ratio 0%

BABY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BABY stock intrinsic value calculation we used $501 million for the last fiscal year's total revenue generated by Natus Medical. The default revenue input number comes from 2017 income statement of Natus Medical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BABY stock valuation model: a) initial revenue growth rate of 31.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.9%, whose default value for BABY is calculated based on our internal credit rating of Natus Medical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Natus Medical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BABY stock the variable cost ratio is equal to 85.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BABY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Natus Medical.

Corporate tax rate of 27% is the nominal tax rate for Natus Medical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BABY stock is equal to 1.9%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BABY are equal to 57.4%.

Life of production assets of 10 years is the average useful life of capital assets used in Natus Medical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BABY is equal to 9.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $422 million for Natus Medical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 33 million for Natus Medical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Natus Medical at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
NURO NeuroMetrix 1.31 6.35  str.buy
CASM CAS Medical Sy 1.97 0.02  str.sell
MASI Masimo 99.38 173.63  str.buy
HOLX Hologic 41.09 22.04  sell
BDX Becton Dickins 245.13 144.47  sell
PHG Koninklijke Ph 43.51 32.44  hold

COMPANY NEWS

▶ Natus Medical appoints Kennedy as CEO, Paul as chair   [Jul-11-18 05:18PM  MarketWatch]
▶ Natus Medical Announces Leadership Changes   [05:00PM  GlobeNewswire]
▶ Hedge fund Voce's nominees elected to Natus board   [Jun-24-18 01:13PM  Reuters]
▶ Hedge fund Voce's nominees elected to Natus board   [Jun-22-18 02:11PM  Reuters]
▶ Natus Medical Comments on ISS Report   [Jun-11-18 08:00AM  GlobeNewswire]
▶ Natus Annual Meeting - Whats at Stake?   [Jun-06-18 08:30AM  GlobeNewswire]
▶ Natus to Present at Jefferies 2018 Healthcare Conference   [May-24-18 07:00AM  GlobeNewswire]
▶ Natus Medical Files Definitive Proxy Materials   [May-18-18 08:00AM  GlobeNewswire]
▶ Natus Medical: A Tale of Two Halves of the Year?   [Apr-26-18 04:04PM  Motley Fool]
▶ Natus Medical: 1Q Earnings Snapshot   [06:16AM  Associated Press]
▶ [$$] Spat, Weak Guidance Lead to Board Fight at Natus Medical   [Mar-20-18 01:40PM  The Wall Street Journal]
▶ Natus to Present at 30th Annual Roth Conference   [Mar-05-18 07:00AM  GlobeNewswire]
▶ Natus Announces $30 Million Share Repurchase Program   [Feb-22-18 07:00AM  GlobeNewswire]
▶ Natus Medical Hears a Rebound Coming   [Feb-09-18 04:30PM  Motley Fool]
▶ Why Natus Medical Incorporated Stock Lost 19% in January   [Feb-08-18 03:05PM  Motley Fool]
▶ Natus Medical reports 4Q loss   [07:03AM  Associated Press]
▶ Why Natus Medical Inc Sank Lower Today   [Jan-08-18 12:32PM  Motley Fool]
▶ 4 Growth Stocks to Pick From a Choppy MedTech Market   [Dec-14-17 03:05PM  InvestorPlace]
▶ Stocks With Rising Relative Strength: Natus Medical   [03:00AM  Investor's Business Daily]
▶ Stocks To Watch: Natus Medical Sees Relative Strength Rating Rise To 84   [Nov-08-17 03:00AM  Investor's Business Daily]
▶ Natus Medical Shows Rising Relative Strength; Still Shy Of Key Benchmark   [Oct-31-17 03:00AM  Investor's Business Daily]
▶ Oh Baby! Natus Medical Inc. Beats and Raises Guidance   [Oct-26-17 04:07PM  Motley Fool]
▶ Natus Medical reports 3Q loss   [Oct-25-17 06:23AM  Associated Press]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.